Project Grant K23HL189018
Award Date 8/15/26
Completion Date 5/31/30
Dollars Obligated $313K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Durham, NC 27710, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Duke University $238,516 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct admixture mapping of genetic modifiers in sickle cell disease. The research leverages the National Heart, Lung, and Blood Institute's TOPMed program, which includes multiple cross-sectional adult sickle cell disease cohorts totaling more than 4,000 participants with whole genome sequencing data and extensive clinical...
- The National Institute of Neurological Disorders and Stroke awarded Duke University $3.119 million on September 18, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate computational and clinical tools for understanding pain variability in sickle cell disease. The funded work constitutes a prospective cohort study enrolling 1,250 individuals aged 15 years and older living with sickle cell disease in the United States. Over three years, the research...
- The National Heart, Lung, and Blood Institute awarded Emory University $797,648 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate red blood cell-bound cell-free DNA as a predictor of acute anemia in sickle cell disease. The research examines whether elevated levels of cell-free DNA released during vaso-occlusive complications in sickle cell disease bind to toll-like receptor 9 (TLR9) on red blood cells, thereby modulating red blood cell clearance...
- The National Heart, Lung, and Blood Institute awarded Emory University $1,288,327 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on red blood cell survival in recipients with sickle cell disease. The research evaluates the impact of donor and recipient factors on transfused red blood cell (RBC) survival in sickle cell disease patients and examines mechanisms contributing to RBC clearance. The study proposes an experimental,...
- The National Heart Lung and Blood Institute awarded $1.449 million to the University of North Carolina at Chapel Hill on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837, R01HL177199) to conduct a multi-site prospective study examining the prevalence, clinical impact, and treatment response of sleep-associated hypoxemia in adults with sickle cell anemia. The study enrolls adult patients with homozygous sickle cell anemia (SCA) at four institutions—University of...
- The National Heart, Lung, and Blood Institute awarded Rutgers The State University of New Jersey, School of Nursing, $117,750 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct proteomic profiling and neurocognitive assessment to uncover stroke mechanisms in adults with sickle cell disease. The study quantifies neurodegeneration-associated and mitochondrial proteins in a cohort of 90 sex- and age-matched adults comprising 30 healthy controls, 30...
- The National Heart, Lung, and Blood Institute awarded the University of Cincinnati Sponsored Research Services Division $186,613 in project grant funding on April 10, 2026, to investigate activated microglia and cognitive deficits in adults with sickle cell disease. The research measures the density and distribution of regional and whole-brain activated microglia in 45 individuals with sickle cell disease compared to 15 healthy controls using diffusion MRI neuroimaging biomarkers. The study...
- The National Heart, Lung, and Blood Institute awarded $1.834 million to St. Jude Children's Research Hospital Inc. on July 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to test senescence-targeting therapies for improving hematopoietic stem cell function and mobilization in sickle cell disease. The research addresses pathologic bone marrow stress in sickle cell disease patients, which damages and depletes hematopoietic stem and progenitor cells and selects for...
- The National Heart, Lung, and Blood Institute awarded Yale University $313,649 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2026, to derive and validate a clinical prediction rule identifying febrile children and adolescents with sickle cell disease at low risk for bacteremia. The project addresses overtreatment of febrile children with sickle cell disease in emergency departments. Existing clinical guidelines recommend aggressive evaluation for bacteremia due...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $240,707 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms of marginal zone B cell depletion in sickle cell disease spleen tissue. The research addresses adaptive immune dysfunction in sickle cell disease, a genetic hemolytic anemia affecting millions worldwide. Prior K23 award work identified an age-related decline in unswitched memory B cells in children...